Nautilus Biotechnology (NAUT) to Release Quarterly Earnings on Thursday

Nautilus Biotechnology (NASDAQ:NAUT) is expected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Nautilus Biotechnology to post earnings of ($0.14) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Nautilus Biotechnology Stock Performance

Shares of NASDAQ:NAUT opened at $2.84 on Wednesday. Nautilus Biotechnology has a 52-week low of $0.62 and a 52-week high of $2.93. The stock has a market capitalization of $358.71 million, a price-to-earnings ratio of -5.68 and a beta of 1.49. The stock’s 50-day simple moving average is $2.12 and its two-hundred day simple moving average is $1.55.

Institutional Investors Weigh In On Nautilus Biotechnology

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE lifted its position in shares of Nautilus Biotechnology by 37.1% in the fourth quarter. Bank of America Corp DE now owns 49,419 shares of the company’s stock valued at $83,000 after acquiring an additional 13,363 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Nautilus Biotechnology in the 1st quarter worth approximately $194,000. Acadian Asset Management LLC lifted its holdings in Nautilus Biotechnology by 468.3% in the 1st quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock worth $51,000 after purchasing an additional 50,871 shares in the last quarter. XTX Topco Ltd boosted its stake in Nautilus Biotechnology by 86.2% in the 2nd quarter. XTX Topco Ltd now owns 66,194 shares of the company’s stock worth $48,000 after purchasing an additional 30,641 shares during the period. Finally, Qube Research & Technologies Ltd purchased a new stake in Nautilus Biotechnology during the 2nd quarter valued at approximately $45,000. 50.71% of the stock is owned by institutional investors.

Analysts Set New Price Targets

NAUT has been the subject of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Thursday, January 22nd. Wall Street Zen raised shares of Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research report on Tuesday, November 18th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell” and an average target price of $2.50.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.